Last 7 days
-3.0%
Last 30 days
-11.2%
Last 90 days
-11.0%
Trailing 12 Months
1.5%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 115.9B | 26.2B | -9.16% | -12.25% | 14.64 | 4.43 | -0.48% | 38.34% |
GILD | 96.2B | 27.0B | -7.94% | 24.63% | 17.23 | 3.56 | -1.56% | 23.65% |
MRNA | 48.5B | 15.1B | -3.43% | -7.04% | 10.13 | 3.22 | -33.37% | -67.32% |
BIIB | 43.1B | 10.1B | 3.69% | 46.24% | 13.77 | 4.27 | -6.61% | 115.98% |
MID-CAP | ||||||||
NBIX | 8.9B | 1.6B | -11.20% | 1.54% | 138.97 | 5.56 | 32.38% | -10.36% |
DNLI | 4.1B | - | 22.94% | 24.01% | -11.06 | 37.77 | 122.90% | -29.67% |
BEAM | 2.4B | 76.7M | 5.96% | -0.58% | -7.62 | 31.42 | 41.73% | -32.75% |
BBIO | 2.2B | 107.9M | -3.78% | 107.70% | -4.55 | 20.44 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.6B | 119.0M | 22.46% | 21.04% | -5.77 | 13.53 | -69.61% | -584.39% |
REPL | 1.1B | 10.0M | 16.71% | 38.03% | -6.34 | 110.4 | 215.65% | -47.65% |
NVAX | 622.2M | - | -4.25% | -84.68% | -0.54 | 0.31 | 72.89% | 12.32% |
FATE | 503.7M | 136.9M | -11.86% | -77.13% | -2.14 | 3.68 | 116.83% | -0.93% |
SGMO | 210.2M | 241.0M | -21.74% | -64.41% | -1.65 | 0.87 | 113.96% | 27.87% |
VXRT | 162.7M | 697.0K | 67.22% | -64.71% | -1.51 | 233.45 | 47.98% | -35.48% |
IBIO | 9.3M | - | -31.01% | -87.63% | -0.12 | 3.21 | 0.51% | -129.47% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 7.4% | 1,599 | 1,489 | 1,389 | 1,297 | 1,208 |
S&GA Expenses | 5.6% | 795 | 753 | 726 | 695 | 655 |
EBITDA | 116.6% | 236 | 109 | 46.00 | 129 | - |
EBITDA Margin | 102.1% | 0.16* | 0.08* | 0.04* | 0.11* | - |
Earnings Before Taxes | -58.3% | 89.00 | 214 | 82.00 | 15.00 | 96.00 |
EBT Margin | 142.7% | 0.14* | 0.06* | 0.01* | 0.08* | - |
Interest Expenses | -21.1% | 6.00 | 7.00 | 13.00 | 18.00 | 22.00 |
Net Income | -58.6% | 64.00 | 155 | 58.00 | 12.00 | 71.00 |
Net Income Margin | 147.6% | 0.10* | 0.04* | 0.01* | 0.06* | - |
Free Cahsflow | 82.4% | 323 | 177 | 133 | 102 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -0.4% | 2,360 | 2,369 | 2,143 | 2,006 | 2,145 |
Current Assets | -1.4% | 1,433 | 1,454 | 1,206 | 1,019 | 1,018 |
Cash Equivalents | -57.6% | 112 | 263 | 212 | 163 | 270 |
Inventory | -4.8% | 33.00 | 35.00 | 37.00 | 29.00 | 29.00 |
Net PPE | 7.2% | 63.00 | 59.00 | 61.00 | 67.00 | 64.00 |
Liabilities | 2.2% | 675 | 661 | 599 | 582 | 753 |
Current Liabilities | -30.4% | 374 | 538 | 485 | 286 | 254 |
Shareholder's Equity | -1.4% | 1,685 | 1,708 | 1,545 | 1,423 | 1,391 |
Retained Earnings | -18.8% | -483 | -406 | -495 | -564 | -547 |
Additional Paid-In Capital | 2.3% | 2,171 | 2,122 | 2,054 | 2,000 | 1,948 |
Shares Outstanding | 1.0% | 98.00 | 97.00 | 96.00 | 96.00 | 96.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -25.0% | 255 | 339 | 201 | 164 | 129 |
Share Based Compensation | 1.7% | 176 | 173 | 165 | 159 | 138 |
Cashflow From Investing | -5.9% | -187 | -177 | -37.80 | -102 | -224 |
Cashflow From Financing | 0.9% | -232 | -234 | -257 | -261 | 18.00 |
85.8%
49.6%
17.7%
Y-axis is the maximum loss one would have experienced if Neurocrine Biosciences was unfortunately bought at previous high price.
21.2%
10.2%
-0.6%
-8.5%
FIve years rolling returns for Neurocrine Biosciences.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | Toroso Investments, LLC | new | - | 416,000 | 416,000 | 0.01% |
2023-05-23 | Front Row Advisors LLC | reduced | -1.49 | -1,000 | 7,000 | -% |
2023-05-22 | Raleigh Capital Management Inc. | added | 78.38 | 2,262 | 6,681 | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -9.57 | -16,845,700 | 55,248,300 | 0.02% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 377,000 | 0.02% |
2023-05-22 | PUTNAM INVESTMENTS LLC | unchanged | - | -182,830 | 1,043,690 | -% |
2023-05-22 | American Trust | reduced | -39.97 | -383,161 | 396,782 | 0.03% |
2023-05-19 | Coppell Advisory Solutions LLC | sold off | -100 | -50,523 | - | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -11.19 | -6,804,000 | 20,696,000 | 0.03% |
2023-05-18 | JPMORGAN CHASE & CO | reduced | -0.65 | -40,960,400 | 218,231,000 | 0.03% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | janus henderson group plc | 2.5% | 2,415,638 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.72% | 9,340,295 | SC 13G/A | |
Jan 23, 2023 | blackrock inc. | 13.1% | 12,627,403 | SC 13G/A | |
Feb 14, 2022 | price t rowe associates inc /md/ | 4.5% | 4,359,645 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 9.26% | 8,787,991 | SC 13G/A | |
Feb 10, 2022 | janus henderson group plc | 7.8% | 7,445,839 | SC 13G/A | |
Jan 27, 2022 | blackrock inc. | 12.1% | 11,476,545 | SC 13G/A | |
Jan 26, 2022 | blackrock inc. | 12.1% | 11,476,545 | SC 13G/A | |
Aug 10, 2021 | fmr llc | - | 0 | SC 13G/A | |
Apr 12, 2021 | blackrock inc. | 11.7% | 10,989,646 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 58.60 -35.76% | 74.82 -17.98% | 138.36 51.68% | 234.88 157.49% | 403.18 341.99% |
Current Inflation | 53.71 -41.12% | 67.54 -25.96% | 121.76 33.48% | 203.17 122.73% | 345.03 278.24% |
Very High Inflation | 47.68 -47.73% | 58.74 -35.61% | 102.21 12.05% | 166.50 82.53% | 278.42 205.22% |
Date Filed | Form Type | Document | |
---|---|---|---|
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 8-K | Current Report | |
May 11, 2023 | 4/A | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-01 | Cooke Julie | sold | -1,184,050 | 103 | -11,397 | chief human resources officer |
2023-05-01 | RASTETTER WILLIAM H | sold | -436,135 | 101 | -4,300 | - |
2023-05-01 | RASTETTER WILLIAM H | acquired | 96,913 | 12.71 | 7,625 | - |
2023-04-25 | Cooke Julie | sold | -10,382 | 103 | -100 | chief human resources officer |
2023-04-24 | ROBERTS EIRY | sold | -1,490,060 | 103 | -14,400 | chief medical officer |
2023-04-21 | RASTETTER WILLIAM H | sold | -633,787 | 105 | -6,034 | - |
2023-04-21 | RASTETTER WILLIAM H | acquired | 136,823 | 12.71 | 10,765 | - |
2023-04-19 | RASTETTER WILLIAM H | acquired | 20,463 | 12.71 | 1,610 | - |
2023-04-19 | RASTETTER WILLIAM H | sold | -94,818 | 105 | -903 | - |
2023-02-08 | GORMAN KEVIN CHARLES | sold | -237,185 | 104 | -2,274 | chief executive officer |
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenues: | ||
Revenues | $ 420.4 | $ 310.6 |
Operating expenses: | ||
Cost of revenues | 8.5 | 4.6 |
Research and development | 139.5 | 102.2 |
Acquired in-process research and development | 143.9 | 0.0 |
Selling, general and administrative | 242.7 | 200.7 |
Total operating expenses | 534.6 | 307.5 |
Operating (loss) income | (114.2) | 3.1 |
Other income (expense): | ||
Interest expense | (1.1) | (2.6) |
Unrealized gain on equity security investments | 2.2 | 19.9 |
Investment income and other, net | 9.8 | 1.0 |
Total other income, net | 10.9 | 18.3 |
(Loss) income before (benefit from) provision for income taxes | (103.3) | 21.4 |
(Benefit from) provision for income taxes | (26.7) | 7.5 |
Net (loss) income | (76.6) | 13.9 |
Foreign currency translation adjustments, net of tax | 1.2 | 0.0 |
Unrealized gain (loss) on debt securities available-for-sale, net of tax | 4.0 | (7.6) |
Comprehensive (loss) income | $ (71.4) | $ 6.3 |
(Loss) earnings per share: | ||
Basic (in USD per share) | $ (0.79) | $ 0.15 |
Diluted (in USD per share) | $ (0.79) | $ 0.14 |
Weighted-average shares outstanding: | ||
Basic (in shares) | 97.1 | 95.3 |
Diluted (in shares) | 97.1 | 97.6 |
Net product sales | ||
Revenues: | ||
Revenues | $ 415.3 | $ 305.0 |
Collaboration revenues | ||
Revenues: | ||
Revenues | $ 5.1 | $ 5.6 |
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 103.8 | $ 262.9 |
Debt securities available-for-sale | 790.8 | 726.4 |
Accounts receivable | 391.6 | 350.0 |
Inventories | 33.4 | 35.1 |
Other current assets | 113.2 | 79.1 |
Total current assets | 1,432.8 | 1,453.5 |
Deferred tax assets | 337.4 | 305.9 |
Debt securities available-for-sale | 244.6 | 299.4 |
Right-of-use assets | 84.4 | 87.0 |
Equity security investments | 135.7 | 102.1 |
Property and equipment, net | 62.8 | 58.6 |
Intangible assets, net | 37.2 | 37.2 |
Other assets | 24.9 | 25.0 |
Total assets | 2,359.8 | 2,368.7 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 355.7 | 347.6 |
Convertible senior notes | 0.0 | 169.4 |
Other current liabilities | 18.4 | 20.7 |
Total current liabilities | 374.1 | 537.7 |
Convertible senior notes | 169.5 | 0.0 |
Noncurrent operating lease liabilities | 90.4 | 93.5 |
Other long-term liabilities | 41.3 | 29.7 |
Total liabilities | 675.3 | 660.9 |
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding | 0.0 | 0.0 |
Common stock, $0.001 par value; 220.0 million shares authorized; 97.5 million and 96.5 million shares issued and outstanding, respectively | 0.1 | 0.1 |
Additional paid-in capital | 2,170.5 | 2,122.4 |
Accumulated other comprehensive loss | (2.7) | (7.9) |
Accumulated deficit | (483.4) | (406.8) |
Total stockholders’ equity | 1,684.5 | 1,707.8 |
Total liabilities and stockholders’ equity | $ 2,359.8 | $ 2,368.7 |